| ObjectiveThe present study was designed to investigate the prognostic value of pretreatment plasma hyperfibrinogenemia in Chinese Patients with Early-stage And Locally Advanced Cervical Cancer.MethodsData from a consecutive cohort of 290 cases with newly diagnosed early stage and locally advanced cervical cancer between 2005 and 2010 were retrospectively evaluated.Healthy controls were selected from a cancer-tree population in the same region.Plasma fibrinogen level was determined by the Clauss method.The optimal cutoff value was defined as 4.0 g/L according to the instructions' recommendation.ResultsThe proportion of hyperfibrinogenemia was significantly higher in cervical cancer patients than those in healthy controls(47.6%vs 13.9%).In addition,pretreatment plasma hyperfibrinogenemia was associated with advanced tumor size,tumor stage,more recurrences and deaths.Moreover,univariate survival analysis revealed that compared to those with normal plasma fibrinogen levels,patients with hyperfibrinogenemia tended to have poorer disease-free survival(DFS)[hazard ratio(HR),3.596;95%confidence interval(CI),2.204-4.350;P<0.001]and overall survival(OS)(HR,4.501;95%CI,2.990-5.782;P<0.001).In the multivariate Cox regression models,they remained independent predictors for impaired DFS(HR,2.285;95%CI,1.287-3.236;P<0.001)and OS(HR,2.595;95%CI,1.462-4.605;P=0.001)after adjusting for other confounding variables.Meanwhile,tumor size,lymphatic metastasis and tumor stage were other independent prognostic factors for cervical cancer patients(P<0.05).ConclusionsPretreatment plasma hyperfibrinogenemiamight serve as an independent biochemical marker topredict unfavorable survivalinChinese patients with non-metastatic cervical cancer.ObjectiveThe present study was to evaluate the prognostic value of pretreatment fibrinogen and albumin(FA)score in patients with early-stage and locally advanced cervical cancer.MethodsClinicopathologic variables,pretreatment fibrinogen and albumin levels were retrospectively reviewed in 284 cases with newly diagnosed stage I-III cervical cancer between 2005 and 2014.The optimal cut-off value was defined as 4.0 g/L for fibrinogen according to manufacturer's recommendations,and 37.7 g/L for albumin as the lower quartile.Subjects with decreased albumin and elevated fibrinogen levels were allocated a score of 2,those with only one of these two abnormalities were assigned a score of 1,and those with neither of the two abnormalities were allocated a score of 0.Results(1)114(40.1%),131(46.1%),and 39(13.8%)patients had an FA score of 0,1,and 2,respectively.(2)Pretreatment FA score was significantly associated with tumor size,lymph node involvement,clinical stage,recurrence and death.(3)Additionally,patients with a high pretreatment FA score had shorter disease free survival(DFS)(P<0.001)and overall survival(OS)(P<0.001).(4)Furthermore,multivariate Cox regression analysis revealed that pretreatment FA score remained an independent prognostic indicator for both DFS(P=0.004)and OS(P=0.018).ConclusionHigh pretreatment FA score could significantly predict unfavorable long-term survival for patients with early-stage and locally advanced cervical cancer.ObjectiveThis study was performed to evaluate the prognostic significance of the pretreatment serum gamma-glutamyltransferase(GGT)levels in a Chinese cohort of patients with early-stage or locally advanced cervical cancer.MethodsThe pretreatment serum GGT levels were examined in 290 cervical cancer patients with stage I-III disease and 230 healthy controls selected from a cancer-free population in the same region.Patients were assigned to normal or high-risk GGT groups,as previously described,and the GGT levels were correlated to clinicopathologic parameters and survival data.ResultsThe GGT levels in cervical cancer patients were significantly higher than those in healthy controls(35.6 ± 29.1 vs.24.1±14.7 U/L,P<0.001).In addition,thepretreatment serum GGT levels were associated with the histology type(P=0.023),lymph node involvement(P=0.040),stage(P=0.029),recurrence(P=0.015)and death(P=0.005),but not with age(P=0.432),tumor size(P=0.067)or degree of differentiation(P=0.901).Moreover,univariate survival analysis revealed that patients with high GGT levels tended to have poorer disease-free survival(DFS)[hazard ratio(HR),1.721;95%confidence interval(Cl),1.189-2.491;P=0.004]and overall survival(OS)(HR,1.929;95%Cl,1.294-2.876;P=0.001)compared to those with normal GGT levels.However,a multivariate Cox-regression model did not support these data(HR,1.373;95%CI,0.925-2.039;P=0.116 for DFS and HR,1.357;95%Cl,0.887-2.078;P=0.160 for OS,respectively)after adjusting for other confounding variables.ConclusionsHigh pretreatment serum GGT was associated with more advanced tumor behavior,but could not serve as an independent prognostic indicator in patients with early-stage or locally advanced cervical cancer. |
PDF Full Text Request